title: [Novel possibilities of antithrombotic therapy in patients with chronic heart failure].
abstract: Modern approaches to prevention of venous thromboembolic complications in patients with chronic heart failure are analyzed in this review which contains results of large studies of low molecular weight heparins. In MEDENOX trial the use of enoxaparin in medical patients was associated with 63% reduction of risk of thrombosis. The authors own experience showed that 2 weeks of therapy with enoxaparin in patients with chronic stage IIB-III heart failure caused significant lowering of soluble fibrin-monomer complexes, fibrinogen, and index of turbo-dynamic potential. These changes evidenced for decreased intravascular blood coagulation. Thus enoxaparin can be effectively used for prevention of thrombosis and thromboembolism in patients with chronic heart failure. Novel antithrombotic agents fondaparinux, idraparinux, ximelagatran, recombinant thrombomodulin are perspective medications for prevention of venous thromboses and embolism in medical patients.
authors.forename: L I
authors.initials: LI
authors.lastname: Ol'binskaia
authors.forename: K Iu
authors.initials: KIu
authors.lastname: Kolosova
authors.forename: S G
authors.initials: SG
authors.lastname: Nesterova
authors.forename: T D
authors.initials: TD
authors.lastname: Egorova
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Fedorova
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001384:Azetidines / Q000008:administration & dosage / Q000627:therapeutic use; D001596:Benzylamines / Q000008:administration & dosage / Q000627:therapeutic use; D017985:Dalteparin / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077425:Fondaparinux; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D015337:Multicenter Studies as Topic; D009844:Oligosaccharides / Q000008:administration & dosage / Q000627:therapeutic use; D010919:Placebos; D011134:Polysaccharides / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013923:Thromboembolism / Q000517:prevention & control*; D018180:Thrombomodulin / Q000008:administration & dosage / Q000627:therapeutic use; D013927:Thrombosis / Q000517:prevention & control*; D013997:Time Factors; D020246:Venous Thrombosis / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D009844:Oligosaccharides; D010919:Placebos; D011134:Polysaccharides; D018180:Thrombomodulin; C426686:ximelagatran; C479958:idraparinux; D000077425:Fondaparinux; D017985:Dalteparin